Chronisches Nierenversagen – Update 2018

Zusammenfassung

Die CANVAS-Programm-Studie hat mit Canagliflozin die Nephroprotektion, welche mit Empagliflozin publiziert wurde (EMPA-REG-Outcome-Studie), bestätigt. Die Therapie mit Liraglutide in der LEADER-Studie suggeriert Nephroprotektion über eine Reduktion der Albuminurie und geringerem eGFR-Abfall (eGFR: geschätzte glomeruläre Filtrationsrate) in Subgruppen/Stadien der diabetischen Nierenerkrankung. Im Juli 2017 erfolgte ein Update der KDIGO (Kidney Disease: Improving Global Outcomes) -2009-Leitlinie zur Diagnostik und Therapie der Störungen des Mineral- und Knochenhaushalts bei chronischen Nierenerkrankungen. Änderungen betrafen die Knochendichtemessung, die Therapie von Hyperphosphatämie und Hyperparathyreoidismus im Prädialysestadium und eine Warnung vor exzessiver Kalziumexposition. Ein neues parenterales Kalzimimetikum Zwei Phase-III-Studien zum Einsatz eines neuen parenteralen Kalzimimetikums (Etelcalcitid) wurden publiziert.

• Literatur

• 1 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
• 2 Wanner C, Inzucchi SE, Lachin JM. et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
• 3 Cherney DZI, Zinman B, Inzucchi SE. et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diab Endo 2017; 5: 610-621
• 4 Wanner C. EMPA-REG OUTCOME: The Nephrologist’sPoint of View. Am J Med 2017; 130: 63-72
• 5 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657
• 6 Wanner C, Lachin JM, Inzucchi SE. et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2017 DOI: doi:10.1161/CIRCULATIONAHA.117.028268
• 7 Ketteler M, Block GA, Evenepoel P. et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’schanged and why it matters. Kidney Int 2017; 92: 26-36
• 8 Iimori S, Mori Y, Akita W. et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients–a single-center cohort study. Nephrol Dial Transplant 2012; 27: 345-351
• 9 Naylor KL, Garg AX, Zou G. et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 2015; 10: 646-653
• 10 West SL, Lok CE, Langsetmo L. et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 2015; 30: 913-919
• 11 Yenchek RH, Ix JH, Shlipak MG. et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012; 7: 1130-1136
• 12 Block GA, Kilpatrick RD, Lowe KA. et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 2013; 8: 2132-2140
• 13 Block GA, Wheeler DC, Persky MS. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
• 14 Hill KM, Martin BR, Wastney ME. et al. Oral Kalzium carbonate affects Kalzium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int 2013; 83: 959-966
• 15 Moe SM, Chertow GM, Parfrey PS. et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 2015; 132: 27-39
• 16 Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7: 487-493
• 17 Di Iorio B, Molony D, Bell C. et al. Sevelamer versus Kalzium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62: 771-778
• 18 Thadhani R, Appelbaum E, Pritchett Y. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684
• 19 Wang AY, Fang F, Chan J. et al. Effect of paricalcitol on left ventricular mass and function in CKD–the OPERA trial. J Am Soc Nephrol 2014; 25: 175-186
• 20 Block GA, Bushinsky DA, Cunningham J. et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA 2017; 317: 146-155
• 21 Block GA, Bushinsky DA, Cheng S. et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 2017; 317: 156-164